Roche: FDA approves Lucentis syringe for diabetes

(CercleFinance.com) - The US Food and Drug Administration has approved Roche's Lucentis prefilled syringe as a new method of treating diabetic retinopathy, a complication of diabetes, the Swiss drugmaker said on Thursday.


In April 2017, Lucentis became the first FDA-approved medicine to treat all forms of diabetic retinopathy in people with or without diabetic macular oedema, an eye disease that results in swelling in the back of the eye.

Diabetic retinopathy affects nearly 7.7 million people in the US, Roche said.

The Lucentis 0.3-mg prefilled syringe is expected to be available in the second quarter of 2018.

In its 0.5 mg version, the product has already been approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Copyright (c) 2018 CercleFinance.com. All rights reserved.